Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
arcticnovartis
Tue, 04/23/2024 – 19:49
Read more about Novartis radioligand therapy Lutat…
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
arcticnovartis
Tue, 04/23/2024 – 07:04
Read more about Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidan…
Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
arcticnovartis
Tue, 04/23/2024 – 07:04
Read more about Novartis, au premier trimestre: croissance à deu…
Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
arcticnovartis
Tue, 04/23/2024 – 07:04
Read more about Novartis erzielt im ersten Quartal ein zweistel…
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
arcticnovartis
Fri, 03/22/2024 – 12:34
Read more about Novartis Fabhalta® (iptacopan) receives…
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
arcticnovartis
Tue, 03/05/2024 – 15:34
Read more about Novartis shareholders approve all resolutions proposed by the Board of Directors a…
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
arcticnovartis
Tue, 03/05/2024 – 15:34
Read more about Les actionnaires de Novartis approuvent toutes le…
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
arcticnovartis
Tue, 03/05/2024 – 15:34
Read more about Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen…
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
arcticnovartis
Mon, 03/04/2024 – 07:19
Read more about Novartis presents new data on safety an…
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
arcticnovartis
Mon, 02/05/2024 – 22:48
Read more about Novartis to strengthen oncology pipeline with agreement…
